Literature DB >> 3009054

Automated kinetic assay of angiotensin-converting enzyme in serum.

B Beneteau, B Baudin, G Morgant, J Giboudeau, F C Baumann.   

Abstract

We have developed and validated an automated kinetic method for angiotensin-converting enzyme (EC 3.4.15.1) on the Olli C + D analyzer, modified from that of Ronca-Testoni (Clin Chem 1983;29:1093-6) with N-[3-(2-furyl)-acryloyl]-L-phenylalanylglycylglycine used as substrate. We have determined appropriate reaction conditions for the assay, verified the principal analytical reliability criteria (repeatability, reproducibility, sensitivity), and established normal reference intervals (mean +/- SD) for the enzyme's activity, using serum of normal adults (100 +/- 35 U/L, n = 150), newborns (130 +/- 27 U/L, n = 10), women taking oral contraceptives (103 +/- 30 U/L, n = 10), smokers (109 +/- 38 U/L, n = 27), and patients with sarcoidosis (220 +/- 48 U/L, n = 15).

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3009054

Source DB:  PubMed          Journal:  Clin Chem        ISSN： 0009-9147            Impact factor:   8.327


  14 in total

1.  Identification of new polymorphisms of the angiotensin I-converting enzyme (ACE) gene, and study of their relationship to plasma ACE levels by two-QTL segregation-linkage analysis.

Authors:  E Villard; L Tiret; S Visvikis; R Rakotovao; F Cambien; F Soubrier
Journal:  Am J Hum Genet       Date:  1996-06       Impact factor: 11.025

2.  Proceedings of the 10th Asian Pacific Congress of Clinical Biochemistry in conjunction with the Australasian Association of Clinical Biochemists' 42nd Annual Scientific Conference.

Authors: 
Journal:  Clin Biochem Rev       Date:  2004

3.  [Expression of angiotensin I converting enzyme in pulmonary hypertension].

Authors:  A M Müller; M Maas; U Kozianka; F E Franke
Journal:  Pathologe       Date:  2006-03       Impact factor: 1.011

4.  [Angiotensin converting enzyme (ACE, CD143) in the regular pulmonary vasculature].

Authors:  A M Müller; K Gruhn; S Lange; F E Franke; K-M Müller
Journal:  Pathologe       Date:  2004-03       Impact factor: 1.011

5.  Segregation and linkage analysis of serum angiotensin I-converting enzyme levels: evidence for two quantitative-trait loci.

Authors:  C A McKenzie; C Julier; T Forrester; N McFarlane-Anderson; B Keavney; G M Lathrop; P J Ratcliffe; M Farrall
Journal:  Am J Hum Genet       Date:  1995-12       Impact factor: 11.025

6.  The effect of saturation of ACE binding sites on the pharmacokinetics of enalaprilat in man.

Authors:  J R Wade; P A Meredith; D M Hughes; H L Elliott
Journal:  Br J Clin Pharmacol       Date:  1992-02       Impact factor: 4.335

7.  Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels.

Authors:  L Tiret; B Rigat; S Visvikis; C Breda; P Corvol; F Cambien; F Soubrier
Journal:  Am J Hum Genet       Date:  1992-07       Impact factor: 11.025

8.  Determination of angiotensin I-converting enzyme activity in equine blood: lack of agreement between methods of analysis.

Authors:  Maria Fernanda de M Costa; Adriana K Carmona; Marcio F M Alves; Timothy M Ryan; Helen M Davies; Garry A Anderson; Ron F Slocombe
Journal:  J Vet Sci       Date:  2011-03       Impact factor: 1.672

9.  New perspectives in the renin-angiotensin-aldosterone system (RAAS) II: albumin suppresses angiotensin converting enzyme (ACE) activity in human.

Authors:  Miklós Fagyas; Katalin Úri; Ivetta M Siket; Gábor Á Fülöp; Viktória Csató; Andrea Daragó; Judit Boczán; Emese Bányai; István Elek Szentkirályi; Tamás Miklós Maros; Tamás Szerafin; István Édes; Zoltán Papp; Attila Tóth
Journal:  PLoS One       Date:  2014-04-01       Impact factor: 3.240

10.  New perspectives in the renin-angiotensin-aldosterone system (RAAS) III: endogenous inhibition of angiotensin converting enzyme (ACE) provides protection against cardiovascular diseases.

Authors:  Miklós Fagyas; Katalin Úri; Ivetta M Siket; Andrea Daragó; Judit Boczán; Emese Bányai; István Édes; Zoltán Papp; Attila Tóth
Journal:  PLoS One       Date:  2014-04-01       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.